Source-grounded facts extracted from IMMUCELL CORP /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IMMUCELL CORP /DE/ entered into Settlement Deed with Norbrook Laboratories Limited valued at $2,000,000 (effective 2026-05-08).
“On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.”
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue $10.4 million.
“health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: ● Domestic sales were $9.7 million in 2026, a 35.7% increase”
IMMUCELL CORP /DE/ announced a impairment with charges of $0.6 million write-down affecting work-in-process colostrum inventory.
“a $0.6 million write-down primarily of work-in-process colostrum inventory that was determined to no longer be fit for processing into First Defense®”
IMMUCELL CORP /DE/ announced a impairment with charges of $0.1 million, non-cash impairment write-down affecting certain property, plant and equipment, unrelated to Re-Tain®.
“the Company has identified a $0.1 million, non-cash impairment write-down of certain property, plant and equipment”
IMMUCELL CORP /DE/ announced a impairment with charges of approximately $2.9 million affecting Re-Tain®.
“The resulting non-cash impairment write-down of property, plant and equipment pertaining to Re-Tain® is currently estimated at approximately $2.9 million”
IMMUCELL CORP /DE/ announced a impairment with charges of approximately $3.6 million in non-cash impairment write-downs affecting Re-Tain® assets and other property, plant and equipment and inventory.
“the Company announced that it will record approximately $3.6 million in non-cash impairment write-downs during the three-month period ended December 31, 2025.”
IMMUCELL CORP /DE/ announced a impairment with charges of approximately $2.3 million affecting production of Re-Tain ®.
“ImmuCell Corporation (“ImmuCell”) has announced strategy changes (see Item 8.01 below) that will result in a material charge for a non-cash impairment write-down of certain property, plant and equipment (primarily equipment) during the fourth quarter of 2025. The affected assets are ones relating to the production of Re-Tain ®. Some but not all of those assets will now be repurposed to manufacture First Defense ®. ImmuCell presently estimates the non-cash impact to profit to be approximately $2.3 million (subject to adjustment pursuant to review of alternate purposing and net realizable value to be completed as part of the financial closing for the quarter and year ending December 31, 2025).”
IMMUCELL CORP /DE/ amended revolving credit of $1 million line of credit with Maine Community Bank (MCB) at variable at the National Prime Rate per annum maturing September 11, 2026.
“On August 20, 2025, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Maine Community Bank (MCB) pursuant to which the Company’s $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings against the Line of Credit is variable at the National Prime Rate per annum.”
IMMUCELL CORP /DE/ incurred loan of $2,327,119 with Maine Community Bank at 6.5% per annum.
“On August 7, 2025, ImmuCell Corporation (the “Company”) entered into a Loan Agreement, Promissory Note, and other definitive agreements covering a loan transaction with Maine Community Bank (MCB). Proceeds from such loan transaction in the principal amount of $2,327,119, and bearing interest at a fixed rate of 6.5% per annum”
Timothy C. Fiori was elected as Chief Financial Officer at IMMUCELL CORP /DE/.
“The Board of Directors of ImmuCell Corporation (the Company) has elected Timothy C. Fiori, age 46, to serve as its Chief Financial Officer effective April 7, 2025.”
IMMUCELL CORP /DE/ reported the quarter ended March 31, 2024 results: revenue $7.3 million, net income Net loss was $438,000, EPS $0.06 per basic share.
“comparable period ended March 31, 2023. Total sales during the trailing twelve-month period ended March 31, 2024 were 33% above the comparable period ended March 31, 2023. The $7.3 million in sales recorded during the first quarter of 2024 represents an all-time quarterly sales record for the Company. The next highest quarter was $6 million recorded during the”
IMMUCELL CORP /DE/ amended First Amendment to Economic Recovery Loan Program Loan Agreement with Finance Authority of Maine valued at amends the FAME Loan Agreement to remove any restrictions on the Company’s ability to issue equity s (effective 2024-04-08).
“In connection with entering into the Sales Agreement, on April 8, 2024, the Company entered into an amendment (the "First Amendment") to the Company's Economic Recovery Loan Program Loan Agreement, by and between the Company and the Finance Authority of Maine dated July 17, 2023 (the "FAME Loan Agreement").”
IMMUCELL CORP /DE/ entered into At The Market Offering Agreement with Craig-Hallum Capital Group LLC valued at up to $11,000,000 of shares of common stock (effective 2024-04-09).
“On April 9, 2024, ImmuCell Corporation (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, up to $11,000,000 of shares of its common stock, par value $0.10 per share (the “Common Stock”).”
IMMUCELL CORP /DE/ reported Q1 2024 results: revenue $ 7.3 million.
“first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended March 31, $ 7.3 million $ 3.4 million $ 3.8 million 111 % During the Twelve-Month Periods Ended March 31, $ 21.3 million $ 16.0 million $ 5.3 million 33 % Total sales during the three-month period ended”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.